Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and adverse event reporting can be found in the footer.

  • Why Nevolat
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • The ideal Nevolat patient
  • How to Administer
    • Dose Titration
    • Method of administration
    • Storage and shelf life
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Nevolat
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • The ideal Nevolat patient
  • How to Administer
    • Dose Titration
    • Method of administration
    • Storage and shelf life
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

Storage and shelf life

Important information on how to store Nevolat®

Two Nevolat packages side by side

Important information on how to store Nevolat®

How to store

Before first use, Nevolat® should be stored in the refrigerator (2˚C–8˚C) but not frozen and placed away from the freezer compartment. The shelf-life of Nevolat® is 24 months, but after first use, should be either stored below 30˚C or refrigerated and used within 30 days.

For full details of storage, please see sections 6.3 and 6.4 of the SmPC.1

 

UV protection of pen

Patients should be advised to keep the pen cap on in order to protect the medication from light. For full details of storage and use of pen, please see sections 6.3 and 6.4 of the SmPC.1

 

Senior man playing tennis
  1. Nevolat® (liraglutide) Summary of Product Characteristics.

000697592 | December 2024

Prescribing information can be found here.

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Zentiva via email to UKMedInfo@zentiva.com
or via phone on 0800 090 2408.

Copyright Zentiva Group, a.s. © 2025

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am